N-ethyl-1'-[(2-{[(ethylamino)carbonyl]amino}-6-methylthieno[2,3-b]pyridin-3-yl)carbonyl]-N-isopropyl-1,4'-bipiperidine-3-carboxamide | 953821-66-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: N-ethyl-1'-[(2-{[(ethylamino)carbonyl]amino}-6-methylthieno[2,3-b]pyridin-3-yl)carbonyl]-N-isopropyl-1,4'-bipiperidine-3-carboxamide
• 英文别名: N-ethyl-1-[1-[2-(ethylcarbamoylamino)-6-methylthieno[2,3-b]pyridine-3-carbonyl]piperidin-4-yl]-N-propan-2-ylpiperidine-3-carboxamide
• CAS: 953821-66-4
• 化学式: C₂₈H₄₂N₆O₃S
• 分子量: 542.746
• InChiKey: YINGFXWMNQPMTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  126
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2009011A1

  公开（公告）日：2008-12-31

  The object of the present invention is to provide a compound having an ACC inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties such as efficacy, duration of activity, specificity, low toxicity and the like. The present invention provides a compound represented by the following formula wherein ring M is a 5- or 6-membered aromatic ring; W is C or N; K is an optionally substituted methylene group or an optionally substituted imino group; R is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted hydroxy group or an optionally substituted heterocyclic group; T and U are independently a hydrogen atom or a substituent or, T and U form, together with ring M, an optionally substituted bicyclic ring; D and G are independently a carbonyl group or a sulfonyl group; ring P is an optionally substituted piperidine or an optionally substituted piperazine; B is CH or N; ring Q is an optionally substituted monocyclic ring; A is C, CH or N; and J is an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group or an optionally substituted amino group, provided that when the W moiety of ring M is =N- or -N=, then U should be absent, or a salt thereof.

  本发明的目的是提供一种具有ACC抑制作用的化合物，用于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等疾病，并具有诸如疗效、活性持续时间、特异性、低毒性等优越特性。本发明提供了以下式所表示的一种化合物，其中环M为5-或6-成员芳香环；W为C或N；K为可选择地取代的亚甲基基团或可选择地取代的亚胺基团；R为氢原子、可选择地取代的碳氢基团、可选择地取代的羟基或可选择地取代的杂环基团；T和U独立地为氢原子或取代基，或T和U与环M一起形成可选择地取代的双环环；D和G独立地为羰基或磺酰基；环P为可选择地取代的哌啶或可选择地取代的哌嗪；B为CH或N；环Q为可选择地取代的单环环；A为C、CH或N；J为可选择地取代的碳氢基团、可选择地取代的杂环基团或可选择地取代的氨基团，前提是当环M的W基团为=N-或-N=时，U应当不存在，或其盐。